Page last updated: 2024-08-18

4-butyrolactone and Diarrhea

4-butyrolactone has been researched along with Diarrhea in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bidoli, P; Cho, BC; Chouaid, C; Corral Jaime, J; Dennis, PA; Garassino, MC; Gray, JE; Huang, Y; Kim, JH; Lena, H; Mazières, J; Park, K; Powderly, J; Rizvi, NA; Soo, RA; Vansteenkiste, J; Wadsworth, C; Wheatley-Price, P	1

Trials

1 trial(s) available for 4-butyrolactone and Diarrhea

Article	Year
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. The Lancet. Oncology, 2018, Volume: 19, Issue:4 Topics: 4-Butyrolactone; Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Aspartate Aminotransferases; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Fatigue; Female; gamma-Glutamyltransferase; Humans; Injection Site Reaction; Lung Neoplasms; Male; Middle Aged; Mutation; Pneumonia; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors	2018

Article

Year

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

The Lancet. Oncology, 2018, Volume: 19, Issue:4

Topics: 4-Butyrolactone; Aged; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Aspartate Aminotransferases; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Fatigue; Female; gamma-Glutamyltransferase; Humans; Injection Site Reaction; Lung Neoplasms; Male; Middle Aged; Mutation; Pneumonia; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors

2018